Back to results
US 2021/0275503 A1Published application
Targeting homologous recombination: a new sythetic lethal therapeutic paradigm
OwnerThomas O'SHEA, Markus RENSCHLER +3inventors
InventorsThomas O'SHEA, Markus RENSCHLER, Todd BOWSER, Jean-Marc LAPIERRE, Kevin MILLS
Life of this patent
Estimating the term…
Abstract
This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for its use, such as to treat cancer.
Claims21
A method of treating a cancer comprising administering to a subject in need thereof Compound 67A
- or a pharmaceutically acceptable salt thereof, at a dosage from about 15 mg to about 700 mg.
-24. (canceled)
Dependencies are inferred from the claim text.